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ABSTRAK 
 
Salah satu faktor risiko penting dalam kanser serviks adalah jangkitan virus papiloma 
manusia (human papillomavirus - HPV). Gen p53 merupakan salah satu sasaran utama 
gen E6 HPV. Protein E6 mempunyai keupayaan untuk merangsang degradasi p53, 
menghentikan beberapa fungsi p53 jenis-liar dan bersaing dengan fungsi lain p53 seperti 
mencegah pertumbuhan kanser. Tujuan kajian ini adalah untuk mengenalpasti perbezaan 
pengekspresan p53 dalam neoplasia serviks pra-malignan dan malignan. Kajian 
retrospektif ini melibatkan 100 kes neoplasia serviks [21 neoplasia serviks intraepitelial 1 
(cervical intraepithelial neoplasia 1- CIN1), 8 CIN2, 25 CIN3, 36 karsinoma sel skuamus, 7 
adenokarsinoma dan 3 adenoskuamus karsinoma). Semua kes dikaji dengan kaedah 
immunohistokimia menggunakan antibodi monoklonal p53. Tiga puluh enam daripada 54 
kes pra-malignan (66.7%) adalah positif terhadap protein p53 berbanding dengan 40 
daripada 46 kes malignan (87.0%) yang menunjukkan kepositifan. Dua puluh sembilan 
daripada 54 (53.7%) kes CIN menunjukkan sama ada pengekspresan fokal atau tiada 
pengekspresan. Sebaliknya, 84.8% (39/46) kes karsinoma invasif menunjukkan 
pengekspresan regional atau pengekspresan keseluruhan. Pengekspresan p53 didapati 
lebih tinggi dalam neoplasia serviks malignan berbanding lesi serviks pra-malignan. Ini 
mencadangkan bahawa pengekspresan p53 bukan satu fenomena awal dalam 
patogenesis kanser serviks. Kajian ini juga menunjukkan terdapat peningkatan peratusan 
pengekspresan p53 dalam CIN2 dan CIN3 berbanding dengan CIN1. Akan tetapi, terdapat 
beberapa kes yang tiada pengekspresan p53 mencadangkan kemungkinan penglibatan 
faktor-faktor lain dan kajian HPV lanjutan adalah diperlukan. 
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ABSTRACT  
 
One of the most important cervical cancer risk factors is human papillomavirus (HPV) 
infection. The p53 gene is one of the most important targets of the HPV E6 gene. E6 
protein has the ability to stimulate p53 degradation, inhibits several functions of wild-type 
p53 and it competes with its function including suppression of malignant growth. The aim 
of this study is to determine the differences in p53 expressions in pre-malignant and 
malignant cervical neoplasms. This is a retrospective study on 100 cases of cervical
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neoplasms. There were 21 cases of CIN 1, 8 cases of CIN 2, 25 cases of CIN 3, 36 cases 
of squamous cell carcinoma, 7 cases of adenocarcinoma and 3 cases of adenosquamous 
carcinoma. All cases were evaluated by immunohistochemistry using p53 monoclonal 
antibody. Thirty six of the 54 pre-malignant cases (66.7%) were positive for p53 protein, in 
contrast to the malignant cases in which, 40 of the 46 cases (87.0%) were positive. The 
majority of CIN showed absent to focal staining (29/54, 53.7%). In contrast, 84.8% (39/46) 
of the invasive carcinoma showed regional to diffuse staining. The expression of p53 is 
greater in the malignant cervical neoplasms than the pre-malignant cervical lesions, 
suggesting that p53 overexpression is not an early phenomenon in the pathogenesis of 
cervical cancer. It is also shown to be slightly higher in percentage in CIN 2 and 3 when 
compared with CIN 1. However, a number of cases were p53 negative, suggesting that 
other factors may be involved and further HPV studies are indicated. 
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INTRODUCTION  
 
Cervical cancer is one of the most common 
cancers in Malaysia. It is the second 
commonest cancer for women. According 
to the Malaysian National Cancer Registry, 
the percentage when compared with the 
rest of the cancer was 12.9% (Lim et al 
2003). One of the most important cervical 
cancer risk factors is human papillomavirus 
(HPV) infection (Munoz et al. 2003). Up to 
now, more than 200 HPV types have been 
identified (Bernard 2005). The International 
Agency for Research on Cancer (IARC) 
studies has provided generic and type-
specific risk estimates for HPV. They 
conclude that there is a strong association 
between HPV and cervical cancer develop-
ment and the risk of developing cancer 
depends on the HPV type (Munoz et al. 
2003). However, HPV infection alone is not 
sufficient for cervical carcinogenesis, and 
attention has been focused on other factors 
important to this process. The development 
and progression of cervical cancer are 
likely to be associated with loss of growth 
suppression (uncontrolled proliferation), 
increased cell growth rates, and angioge-
nesis (Araujo Souza et al. 2003, Tjalma et 
al. 2001, Stanley 2001). 
The p53 gene is located on chromosome 
17p13.1 and it functions as cell-cycle arrest 
and apoptosis in response to DNA 
damage. It is the most common target for 
genetic alteration in human tumours. 
Homozygous loss of p53 gene activity can 
occur in almost every type of cancer, such 
as carcinomas of the lung, colon and 
breast. Normal p53 protein has a very short 
half life and thus the protein level is too low 
to be identified immunohistochemically. In 
contrast, mutant p53 proteins have a 
longer half-life (Finlay et al. 1988) and can 
be easily detected by immunohistochemi-
cal methods. Overexpression of p53 pro-
tein has been identified immunohistochemi-
cally in a variety of tumours. 
The p53 gene is one of the most 
important targets of the HPV E6 gene. It 
was found that E6 protein of high-risk HPV, 
but not of low-risk HPV, could interact with 
p53 in vitro systems. In addition to the 
ability to stimulate p53 degradation, E6 
protein inhibits several functions of wild-
type p53 and it competes with it for the 
most important p53 protein functions inclu-
ding a major role in the suppression of 
malignant growth. It was also shown that 
E6 increased the level of mutagenesis and 
genomic instability (Storey et al. 1998, 
Kisseljov et al. 2000). The resultant loss of 
wild-type p53 increases cellular genomic 
instability after DNA damage. 
The aim of the present study was to 
determine and compare the expressions of 
p53 protein in CIN and cervical cancers, 
which includes squamous cell carcinoma, 
adenocarcinoma and adenosquamous 
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carcinoma. 
 
MATERIALS AND METHODS 
 
Study Design 
 
This is a retrospective study on cases 
diagnosed as CIN, squamous cell 
carcinoma (SCC), adenocarcinoma (AC) 
and adenosquamous carcinoma (ASC) 
obtained from the histopathology records of 
the Department of Pathology, Hospital Uni-
versiti Kebangsaan Malaysia (HUKM), for 
the past seven years from January 1, 1994 
to December 31, 2000. The total number of 
cases was 100. There were 21 cases of 
CIN1, 8 cases of CIN2, 25 cases of CIN3, 
36 cases of SCC, 7 cases of AC and 3 
cases of ASC. 
 
Antibody and immunohistochemistry 
 
Three-micron thick sections were cut from 
the paraffin blocks and mounted on 
sialinized slides. Sections were then depa-
raffinized with 2 changes of xylene and 
rehydrated with four changes of alcohol in 
decreasing concentrations at 3 minutes 
each and then washed in water. The 
sections were then treated with target 
retrieval solution (Dako Corporation 
Denmark) in 1:10 dilution for 20 minutes in 
a water bath at 97oC, followed by cooling 
for 20 minutes in room temperature. This is 
followed by staining using DAKO LSAB+ 
Kit peroxidase (Dako Corporation Den-
mark). The slides were treated with 3% 
hydrogen peroxidase for 10 minutes to 
block endogenous peroxidase activity. 
Then, the slides were washed in Tris-
buffered saline (TBS) for 2 changes at 5 
minutes each. They were then incubated in 
monoclonal antibody p53 protein (D07, 
Dako Corporation Denmark) at a dilution of 
1:500, for 30 minutes. Streptavidin and 
diaminobenzidine (DAB) were added. 
Finally, the slides were counterstained with 
haemotoxylin and eosin. For all cases, the 
same technical personnel performed the 
immunohistochemical stainings. Sections 
of breast cancer were used as positive 
control. 
 
Interpretation of result 
 
All slides were examined under light micro-
scopy. Distinct nuclear staining was re-
garded as p53 positivity. 100 cells were 
evaluated in representative high-power 
fields, to obtain the percentage of cell 
positivity. The pathologists were blinded to 
the clinical diagnoses and origin of the 
samples. The degree of nuclear staining 
was graded depending on the percentage 
of cells stained; grade 0 samples with no 
positivity (negative); grade 1 when less 
than 10% of cells showing positivity (mild 
expression), grade 2 with 11% to 50% 
expression (moderate expression), and 
grade 3 with  greater than 50% expression 
(intense expression). 
 
Statistical analysis 
 
The difference in the degree of p53 protein 
staining between CIN (pre-malignant) and 
carcinoma (malignant) was assessed using 
the Pearson chi-square test. The percent-
age of reactivity in the different individual 
types of cervical neoplasms, i.e., CIN1, 
CIN2, CIN3, SCC, AC and ASC were 
categorical variables. P value was calcula-
ted by SPSS program version 12.0 (SPSS 
Inc., Chicago, IL, USA). Any p value < 0.05 
was considered to be statistically signify-
cant.  
 
RESULTS 
 
Clinical Presentation 
 
The age of clinical presentation of patients 
with cervical neoplasm (CIN and invasive 
carcinoma) ranged from 20 to 72 (43.8) 
years. Patients with cervical carcinoma (32 
to 72, mean 50.3 years) were older than 
those with CIN (20 to 58, mean 37.8 
years); four of our patients who had CIN 
were younger than aged 30 years. The 
distribution of cervical neoplasm in different 
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ethnic groups in Malaysia is 53% Chinese, 
37% Malays and 10% Indian. 
 
p53 Expression 
 
Of the 100 samples obtained, 54 cases 
were pre-malignant lesions (21-CIN1, 8-
CIN2, 25-CIN3), 46 cases were malignant 
(36-SCC, 7-AC and 3-ASC. Positive 
staining for p53 overexpression was 
localized in the nuclei of carcinoma cells 
(Figure 1). The relationship between the 
percentage of cells with p53 expression 
and histological diagnosis is summarized in 
Table 1.  
Thirty six of the 54 pre-malignant cases 
(66.7%) were positive for p53 protein, in 
contrast to the malignant cases in which, 
40 of the 46 cases (87.0%) were positive. 
When the intensity of staining is evaluated, 
grade 3 or intense expression of p53 
protein was observed in 30/46 (65.2%) of 
the malignant cases, while only 8/54 
(14.8%) of the pre-malignant cases were 
immunoreactive. The majority of CIN 
showed negative to grade 1 (mild 
expression) (29/54, 53.7%) immuno-
staining. In contrast, 84.8% (39/46) of the 
invasive carcinoma showed grade 2 to 3 
(moderate to intense) immunostaining. The 
difference in the intensity of p53 protein 
immunoexpression was statistically signi-
ficant (p value <0.05). (Table 1) 
In the pre-malignant lesions, grade 3 or 
intense expression of p53 was noted to be 
higher in CIN3 (6/25, 24%) when compared 
to CIN1 (1/21, 5%) and CIN2 (1/8, 12.5%) 
(Figure 2). However, 7 of the 25 CIN3 
cases were found to be negative for p53 
expression. In malignant cervical lesions, 
SCC (26/36, 72.2%) was observed to have 
the highest percentage of cases with in-
tense p53 expression, this is followed by 
AC (3/7, 42.9%) and ASC (1/3, 33.3%) 
(Figure 3). 
 
DISCUSSION 
 
p53 overexpression is linked with the 
control of cell growth, cell cycle, and 
apoptosis (Levine 1992, Levine et al. 1991, 
Greenblatt et al. 1994). Wild-type p53 
protein usually resides in normal cell 
nuclei. This protein is unstable and has a 
half-life of only 20–30 min, while the mutant 
p53 protein is more stable and has a pro-
longed half-life, resulting in detectable im-
munohistochemical staining (Levine 1992, 
Greenblatt et al. 1994). In uterine cervical 
carcinoma, the detection rate of p53 
overexpression by immunohistochemistry 
has been reported to range from 8 to 74%, 
(Huang et al. 2001, Avall-Lundqvist et al. 
1997, Chen et al. 2000, Oka et al. 1993, 
Brenna et al. 2002, Helland et al. 1993, 
Cavuslu et al. 1997, Dejonge et al. 1999,  
ter Harmsel et al. 1998, Holm et al. 1993) 
and some reports have suggested that p53 
overexpression is important as a prog-
nostic marker (Huang et al. 2001, Avall-
Lundqvist et al. 1997, Chen et al. 2000, 
Oka et al. 1993, Holm et al. 1993). 
In the present study, p53 overexpression 
was detected in 87% of all invasive cervical 
carcinoma cases (40/46). Other investiga-
tors have reported similar findings (Ikuta et 
al. 2005). Our study did not show a 
significant difference in p53 expression 
 
 
Table 1: The percentage of p53 expression in pre-malignant and malignant cervical neoplasms 
 
Histological Diagnosis 
Percentage Of p53 Expression (%) 
0  
(Negative) 
1-10 
(Grade 1) 
11-50 
(Grade 2) 
>50 
(Grade 3) TOTAL 
Pre-Malignant (CIN 1 -3) 18 11 17 8 54 
Malignant (SCC, AC, ASC) 6 1 9 30 46 
Total  100 
(p value <0.05) 
CIN- cervical intraepithelial neoplasia, SCC- squamous cell carcinoma, AC- adenocarcinoma, ASC- 
adenosquamous carcinoma 
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Figure 1: Positive staining for p53 expression in the nuclei of carcinoma cells (A- adenocarcinoma, B- squamous 
cell carcinoma) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CIN- cervical intraepithelial neoplasia 
 
Figure 2:. The distribution of grades of p53 expression in pre-malignant cervical lesions  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SCC- squamous cell carcinoma, ADENOCA- adenocarcinoma, 
ASCA- adenosquamous carcinoma 
 
Figure 3: The distribution of grades of p53 expression in malignant cervical neoplasms 
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between the degrees of CIN, although a 
slight increased in the percentage of cases 
with intense p53 expression was observed 
in CIN3. On the contrary, when pre-
malignant lesions were compared with 
malignant lesions, there is a significant 
difference. This suggests that p53 altera-
tion is not an early event in the pathogen-
nesis of cervical cancer. 
AC (Suzuki et al. 2004) and ASC are 
thought to carry a less favourable prog-
nosis compared to SCC, therefore p53 
expression would be expected to be 
greater in the former. However, p53 
expression was conversely noted to be 
greater in SCC. This finding does not 
reflect the true population because there 
were only 7 cases of AC available for 
evaluation. Many reports have demon-
strated the correlation between p53 gene 
mutation and unfavorable outcome in 
various human cancers, including lung 
(Mitsudomi et al. 2000), breast (Rahko et 
al. 2003), bladder (Lorenzo-Romero et al. 
2003), and cervical (Oka et al. 2000) 
cancer. Previous reports have shown that 
p53 overexpression has a statistically 
significant correlation with poor outcome of 
cervical SCC (Oka et al. 2000) and AC 
(Suzuki et al. 2004). 
Epidemiological studies have shown that 
HPV infection, especially high-risk HPV 
such as HPV types 16 and 18, is involved 
in the carcinogenesis of uterine cervical 
carcinoma (Walboomers et al. 1999, Zur 
Hauzen 2002, Munoz et al. 2003). It is 
known that high-risk HPV produces E6 
oncoprotein, which binds to wild-type p53 
protein to inactivate and degrade tumor 
suppression (Graflund et al. 2002, Kedzia 
et al. 2002, Crook et al. 1992, Werness et 
al. 1990, Akasofu et al. 1995). It is 
therefore postulated that loss of p53 
function due either to binding of HPV 
coding proteins or mutations of the p53 
gene is an important event in the patho-
genesis of cervical carcinomas (Akasofu et 
al. 1995). Further investigations to deter-
mine the HPV status in our population is 
crucial. 
CONCLUSION 
 
In conclusion, the expression of p53 is 
significantly higher in malignant cervical 
neoplasms than in pre-malignant cervical 
lesions, suggesting that p53 overex-
pression is not an early phenomenon in the 
pathogenesis of cervical cancer. It is also 
shown to be slightly higher in percentage in 
CIN2 and CIN3 (high-grade lesion) com-
pared to CIN1 (low-grade lesion). This may 
be due to the fact that high grade lesions 
are more likely to have high risk oncogenic 
human papillomavirus infection as com-
pared to low grade lesions. 
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